Aspen FY revenue up 9% to R38.6bn


Aspen has reported an annual revenue increase of 9 per cent to R38.6 billion boosted by growth from Commercial Pharmaceuticals and 22 per cent increase from its Manufacturing sector. The group has not declared an annual dividend amid the volatile market conditions, but it continues to ramp up production of its COVID-19 treatment drug dexamethasone. Aspen CEO, Stephen Saad joins CNBC Africa for more.

Partner Content

Absa commits to growing African trade with award-winning online platform

Absa launched its online trade finance portal, Trade Management Online, in 2019

Responsible banking in a post-COVID commodity market – Investing responsibly throughout the commodity value chain

While the alcohol sector invariably draws strong feelings from across the philosophical divide during Covid-19, what is indisputable...

A Cyber Pandemic May Be Next: How secure are you in the cloud?

The Coronavirus pandemic has influenced us in a more global way than the Cold War, affecting the environment, industry, finance, healthcare, leisure...

Subscribe to our newsletter

Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox